Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients

NCT02547220 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT02547220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02547220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients
Lead sponsor
Shire
Phase
Phase 3
Overall status
Terminated
Start date
May 20, 2016
Completion date
May 31, 2019
Enrollment
39 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

acute antibody-mediated rejection (amr)